{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T14:22:44Z","timestamp":1724854964866},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,19]]},"DOI":"10.7759\/cureus.67237","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T02:22:11Z","timestamp":1724120531000},"source":"Crossref","is-referenced-by-count":0,"title":["What Is the Appropriate Antibiotic Administration During Tooth Extractions in Patients Receiving High-Dose Denosumab?"],"prefix":"10.7759","author":[{"given":"Eiji","family":"Iwata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ohori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Oko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Minamikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Miyai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shungo","family":"Furudoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings SR","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al.. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009, 361:756-65. 10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2012.01.046","article-title":"Review of current literature and implications of RANKL inhibitors for oral health care providers","volume":"116","author":"Epstein MS","year":"2013","unstructured":"Epstein MS, Ephros HD, Epstein JB. Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013, 116:e437-42. 10.1016\/j.oooo.2012.01.046","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100416","article-title":"Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval","volume":"33","author":"Cadieux B","year":"2022","unstructured":"Cadieux B, Coleman R, Jafarinasabian P, et al.. Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval. J Bone Oncol. 2022, 33:100416. 10.1016\/j.jbo.2022.100416","journal-title":"J Bone Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0154","article-title":"The role of RANK-ligand inhibition in cancer: the story of denosumab","volume":"16","author":"Castellano D","year":"2011","unstructured":"Castellano D, Sepulveda JM, Garc\u00eda-Escobar I, Rodriguez-Antol\u00edn A, Sundl\u00f6v A, Cortes-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011, 16:136-45. 10.1634\/theoncologist.2010-0154","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S14566","article-title":"Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients","volume":"7","author":"Yee AJ","year":"2012","unstructured":"Yee AJ, Raje NS. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging. 2012, 7:331-8. 10.2147\/CIA.S14566","journal-title":"Clin Interv Aging"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5395\/rde.2019.44.e42","article-title":"Dental care for patients taking antiresorptive drugs: a literature review","volume":"44","author":"Song M","year":"2019","unstructured":"Song M. Dental care for patients taking antiresorptive drugs: a literature review. Restor Dent Endod. 2019, 44:e42. 10.5395\/rde.2019.44.e42","journal-title":"Restor Dent Endod"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron R","year":"2011","unstructured":"Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011, 48:677-92. 10.1016\/j.bone.2010.11.020","journal-title":"Bone"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad F","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, et al.. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012, 23:1341-7. 10.1093\/annonc\/mdr435","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline","volume":"37","author":"Yarom N","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, et al.. Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline. J Clin Oncol. 2019, 37:2270-90. 10.1200\/JCO.19.01186","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06634-7","article-title":"Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis","volume":"30","author":"Ikesue H","year":"2022","unstructured":"Ikesue H, Doi K, Morimoto M, et al.. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. Support Care Cancer. 2022, 30:2341-8. 10.1007\/s00520-021-06634-7","journal-title":"Support Care Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06839-4","article-title":"Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study","volume":"30","author":"Hata H","year":"2022","unstructured":"Hata H, Imamachi K, Ueda M, et al.. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study. Support Care Cancer. 2022, 30:4505-14. 10.1007\/s00520-022-06839-4","journal-title":"Support Care Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06732-8","article-title":"Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan","volume":"34","author":"Kunihara T","year":"2023","unstructured":"Kunihara T, Tohmori H, Tsukamoto M, et al.. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan. Osteoporos Int. 2023, 34:1101-9. 10.1007\/s00198-023-06732-8","journal-title":"Osteoporos Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan AA","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, et al.. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015, 30:3-23. 10.1002\/jbmr.2405","journal-title":"J Bone Miner Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06018-x","article-title":"Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases","volume":"29","author":"Ikesue H","year":"2021","unstructured":"Ikesue H, Mouri M, Tomita H, et al.. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Support Care Cancer. 2021, 29:4763-72. 10.1007\/s00520-021-06018-x","journal-title":"Support Care Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-01105-1","article-title":"Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis","volume":"43","author":"Chen J","year":"2021","unstructured":"Chen J, Zhou L, Liu X, Wen X, Li H, Li W. Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis. Int J Clin Pharm. 2021, 43:2-10. 10.1007\/s11096-020-01105-1","journal-title":"Int J Clin Pharm"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-021-02554-8","article-title":"Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials","volume":"16","author":"Jiang L","year":"2021","unstructured":"Jiang L, Cui X, Ma H, Tang X. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials. J Orthop Surg Res. 2021, 16:400. 10.1186\/s13018-021-02554-8","journal-title":"J Orthop Surg Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero SL","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022, 80:920-43. 10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"key":"ref18","unstructured":"Medication-Related Osteonecrosis of the Jaw. Position Paper 2023 of the Japanese Allied Committee\r\non Osteonecrosis of the Jaw. (2023). Accessed: August 9, 2024: http:\/\/www.jsoms.or.jp\/medical\/pdf\/work\/guideline_202307.pdf.."},{"key":"ref19","unstructured":"Japanese Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. (2016). Accessed. August 9, 2024: http:\/\/www.gekakansen.jp\/file\/antimicrobial-guideline.pdf."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0089-x","article-title":"The oral microbiota: dynamic communities and host interactions","volume":"16","author":"Lamont RJ","year":"2018","unstructured":"Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: dynamic communities and host interactions. Nat Rev Microbiol. 2018, 16:745-59. 10.1038\/s41579-018-0089-x","journal-title":"Nat Rev Microbiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003811.pub3","article-title":"Antibiotics to prevent complications following tooth extractions","volume":"2","author":"Lodi G","year":"2021","unstructured":"Lodi G, Azzi L, Varoni EM, et al.. Antibiotics to prevent complications following tooth extractions. Cochrane Database Syst Rev. 2021, 2:CD003811. 10.1002\/14651858.CD003811.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2334\/josnusd.21-0016","article-title":"Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics","volume":"63","author":"Cabras M","year":"2021","unstructured":"Cabras M, Gambino A, Broccoletti R, Sciascia S, Arduino PG. Lack of evidence in reducing risk of MRONJ after teeth extractions with systemic antibiotics. J Oral Sci. 2021, 63:217-26. 10.2334\/josnusd.21-0016","journal-title":"J Oral Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-016-1762-y","article-title":"Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab","volume":"21","author":"Matsumoto A","year":"2017","unstructured":"Matsumoto A, Sasaki M, Schmelzeisen R, Oyama Y, Mori Y, Voss PJ. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. Clin Oral Investig. 2017, 21:127-34. 10.1007\/s00784-016-1762-y","journal-title":"Clin Oral Investig"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2018.08.015","article-title":"Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study","volume":"126","author":"Hallmer F","year":"2018","unstructured":"Hallmer F, Andersson G, G\u00f6trick B, Warfvinge G, Anderud J, Bj\u00f8rnland T. Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018, 126:477-85. 10.1016\/j.oooo.2018.08.015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2021.12.007","article-title":"Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: a nationwide population-based study in Japan","volume":"80","author":"Ishimaru M","year":"2022","unstructured":"Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H. Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: a nationwide population-based study in Japan. J Oral Maxillofac Surg. 2022, 80:714-27. 10.1016\/j.joms.2021.12.007","journal-title":"J Oral Maxillofac Surg"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07134-y","article-title":"Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study","volume":"30","author":"Soutome S","year":"2022","unstructured":"Soutome S, Otsuru M, Murata M, et al.. Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study. Support Care Cancer. 2022, 30:7241-8. 10.1007\/s00520-022-07134-y","journal-title":"Support Care Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvac040","article-title":"Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events","volume":"8","author":"Tamargo J","year":"2022","unstructured":"Tamargo J, Kaski JC, Kimura T, et al.. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events. Eur Heart J Cardiovasc Pharmacother. 2022, 8:738-51. 10.1093\/ehjcvp\/pvac040","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/286261-what-is-the-appropriate-antibiotic-administration-during-tooth-extractions-in-patients-receiving-high-dose-denosumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T02:22:15Z","timestamp":1724120535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/286261-what-is-the-appropriate-antibiotic-administration-during-tooth-extractions-in-patients-receiving-high-dose-denosumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.67237","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}